Vanguard disaggregates holdings; reports 0 shares of Organon (OGN)
Rhea-AI Filing Summary
Organon & Co ownership update: The Vanguard Group filed an amendment noting an internal realignment on January 12, 2026 that led certain subsidiaries and business divisions to report beneficial ownership separately under SEC Release No. 34-39538. The filing states The Vanguard Group beneficially owns 0 shares of Organon common stock, representing 0% of the class. The statement explains the subsidiaries pursue the same investment strategies previously used and that Vanguard Inc. no longer is deemed to beneficially own those securities. The filing is signed by Ashley Grim, Head of Global Fund Administration, dated 03/27/2026.
Positive
- None.
Negative
- None.
FAQ
What does Vanguard's Schedule 13G/A for OGN state?
Does the filing indicate Vanguard subsidiaries still follow the same strategies?
Who signed the Schedule 13G/A amendment for Vanguard on OGN?
Does Vanguard report any >5% holder or third-party interests for OGN?
What is the effect of SEC Release No. 34-39538 mentioned in the filing?